21 results about "Serum transaminase" patented technology

The invention discloses application of auricularia auricula monomer polysaccharide ME-2 in preparation of drugs for preventing and treating fatty liver diseases related to metabolic dysfunction. The research of the invention systematically proves that ME-2 has a remarkable intervention effect on the whole course of MASLD for the first time. The invention discloses a breakthrough function of ME-2 as a liver metabolism regulator for the first time: by directly correcting liver lipid metabolism disorder (such as regulating core genes such as Srebp-1c, ACC1, FASN and the like), liver fatty degeneration can be relieved in a dose-dependent manner in the whole course of MASLD, and the serum transaminase level and dyslipidemia can be reduced. Importantly, the curative effect of the traditional Chinese medicine is derived from intervention on a metabolic root source, and is totally different from a known anti-inflammatory application mechanism. Meanwhile, ME-2 has the remarkable advantages of being clear in structure, taking metabolic regulation as a core, and being safe and non-toxic, and a brand new drug candidate is provided for prevention and treatment of MASLD.

The present invention discloses a pharmaceutical composition for treating non-alcoholic steatohepatitis, liver fibrosis and / or liver cirrhosis, which is prepared from the following raw materials in the following weight ratios: 15-50 parts of Astragalus membranaceus, 5-25 parts of turtle shell, 5-25 parts of Angelica sinensis, 10-30 parts of safflower, 10-30 parts of peach kernel, and 1-10 parts of liquorice. The pharmaceutical composition of the present invention for treating non-alcoholic steatohepatitis can reduce serum transaminase, and significantly reduce lipid deposition, liver tissue inflammation and collagen fiber deposition; the composition of the present invention for treating liver fibrosis can significantly reduce liver tissue pathological inflammation and collagen fiber deposition, as well as the numerical values of related indexes such as serum liver function ALT and AST, and at the same time significantly down-regulate the numerical values of related indexes such as serum PⅢP, PCⅣ, HA and LN, significantly inhibit the activation of hepatic stellate cells (HSCs), the central link of liver fibrosis, significantly reduce the activation of NLRP3 inflammasome in liver tissue, reduce HSC autophagy and activation, and has a good therapeutic effect on both liver fibrosis and liver cirrhosis.

This invention discloses a novel use of carvedilol or its salts and compositions, as well as the composition and its preparation method. The β-blocker or pharmaceutical composition provided by this invention has good efficacy in preventing, treating, and / or alleviating drug-induced liver injury, effectively reducing mortality caused by this disease; simultaneously, it can significantly reduce serum transaminase levels, alleviate symptoms such as liver and spleen edema, and has a good inhibitory effect on pro-inflammatory cytokines. Furthermore, experimental results further indicate that the combination of the β-blocker and pharmaceutically acceptable excipients (steviosides and / or glycyrrhizate) has good safety and is easily dissolved, released, and / or absorbed, improving the bioavailability of carvedilol and exhibiting a synergistic effect, showing promising application prospects.

The invention discloses an aquatic feed based on selenium yeast and application thereof, and belongs to the technical field of aquaculture. The invention relates to an aquatic feed additive based on selenium yeast, which systematically studies the influence of addition of different selenium sources (organic selenium and inorganic selenium) into feed on the growth performance, muscle nutrition, texture characteristics, serum biochemistry and main nutrient components of muscles of hybrid culter. The cultivation efficiency of the hybrid culter can be obviously optimized by enhancing the feed organic selenium, and the specific expression is as follows: the growth rate increase and the feed conversion efficiency improvement have obvious dose dependence; the selenium deposition amount and the crude protein enrichment degree in muscle tissue are synchronously improved, meanwhile, the synergistic effect of essential amino acid composition optimization (EAA / TAA value improvement) and n-3 series fatty acid characteristic enrichment is presented, and the two-way improvement of the nutritional quality and the flavor value is achieved from the molecular nutriology level. Mechanism research shows that the intervention strategy verifies the comprehensive regulation and control effect of the intervention strategy on the body health status by remarkably reducing the activity of serum transaminase (AST and ALT) and the total cholesterol concentration, effectively promoting the steady-state reconstruction of liver metabolism and activating an endogenous antioxidant defense system.

The invention provides a serum marker combination and an analysis system for predicting significant liver lobular inflammation caused by MASLD. Through an advanced targeted metabonomics technology and a machine learning algorithm, a serum metabolite diagnosis model (Inflammation Panel) specially used for diagnosing MASLD-related significant intralobular inflammation (greater than or equal to I2) is developed and verified for the first time. The result analysis shows that the predicted AUC reaches 0.884 (95% CI: 0.791-0.957), the performance is obviously superior to the prediction efficiency of the traditional serum transaminase (AST / ALT), and the blank and deficiency in the aspect of noninvasive diagnosis of the significant liver lobular inflammation (greater than or equal to the I2 stage) of the metabolic dysfunction related fatty liver disease (MASLD) patient in the prior art are filled.

This invention discloses a vitamin A-functionalized polyphenol-phospholipid complex, its preparation method, and its applications, belonging to the field of pharmaceutical formulation and nanodelivery technology. The phospholipid complex comprises a polyphenol drug, a phospholipid material, and a vitamin A phospholipid ligand. The vitamin A phospholipid ligand is formed by vitamin A or its derivatives and a phospholipid derivative containing amino or other reactive groups. The phospholipid complex forms a phospholipid composite structure through non-covalent interactions between the polyphenol drug and the phospholipid material, and the vitamin A phospholipid ligand is inserted into or assembled into the surface or interior of the phospholipid composite structure. Animal experiments show that this phospholipid complex can reduce serum transaminase levels and alleviate the degree of liver fibrosis, and has good blood compatibility and tissue safety. This invention provides an industrially achievable targeted nano-formulation solution for early intervention in liver fibrosis, with promising application prospects.

The invention relates to the technical field of food microorganisms, in particular to a Saccharomyces cerevisiae BR24 (saccharomyces cerevisiae BR24) and application of the Saccharomyces cerevisiae BR24. The Saccharomyces cerevisiae BR24 is preserved in the China General Microbiological Culture Collection Center on December 23, 2024, and the preservation number of the Saccharomyces cerevisiae BR24 is CGMCC (China General Microbiological Culture Collection Center) NO.33166. The Saccharomyces cerevisiae BR24 is named as Saccharomyces cerevisiae BR24. The Saccharomyces cerevisiae BR24 provided by the invention shows good tolerance in a cadmium exposure environment, and by combining with cadmium ions, the level of serum transaminase is reduced, and the expression of metallothionein is promoted, so that the protection and recovery of liver functions are realized.

This invention relates to the application of PRMT4 inhibitors in the preparation of drugs for treating metabolic-associated steatohepatitis (MASH), belonging to the field of fatty liver disease treatment technology. This invention is the first to discover that PRMT4 inhibitors can serve as a novel drug target for treating MASH. Cellular experiments show that PRMT4 inhibitors inhibit palmitic acid-induced hepatocyte steatosis. Animal experiments confirm that PRMT4 inhibitors can improve hepatic fat deposition, inflammatory response, hepatocyte damage, fibrosis, and insulin resistance in high-fat fed mice, and reduce liver tissue and serum triglyceride and transaminase levels. This invention finds that PRMT4 inhibitors mainly inhibit the activation of YAP, a key transcriptional activator involved in lipid and inflammatory metabolism, and the expression of its downstream target genes. Therefore, PRMT4 inhibitors can be used to prepare drugs for treating MASH, with definite and significant efficacy, and have promising medical application prospects.

The invention relates to the technical field of medicinal material treatment, and discloses a method for improving the utilization rate and curative effect of active ingredients of rhizoma polygonati medicinal materials for preventing and treating liver injury, the method comprises the following steps: extracting and concentrating rhizoma polygonati medicinal materials with water, adding 4 times of volume of absolute ethyl alcohol to enable the final concentration of the ethyl alcohol to reach 80%, separating out polysaccharide, and performing centrifugal separation; freeze-drying the polysaccharide precipitate to obtain a polygonatum polysaccharide component; concentrating, freezing and drying the supernate to obtain a non-polysaccharide component enriched with low-content effective components such as flavone, saponin and alkaloid; finally, the polysaccharide component and the non-polysaccharide component are mixed according to the mass ratio of 10: 90 or 30: 70 for use. The anti-liver injury effect of the rhizoma polygonati water extract is superior to that of the traditional rhizoma polygonati water extract, and the liver index and the serum transaminase level during liver injury can be remarkably reduced. According to the technical scheme, the method is easy to implement and low in cost, and the utilization rate of low-content pharmacological active substances in rhizoma polygonati is remarkably increased.

The application discloses application of Rezafetin in preparation of a medicine for treating non-alcoholic fatty liver disease. The application first discovers that the compound has good treatment effect in a non-alcoholic fatty liver disease (NASH) model. Through in-vivo experiments, it is confirmed that in a NASH model mouse, the Rezafetin can significantly reduce pathological characteristics such as liver weight, liver fat level and liver index. Meanwhile, the Rezafetin treatment can significantly reduce the level of serum transaminase (ALT / AST), indicating that the Rezafetin effectively improves liver damage and liver function. The application provides a brand-new and effective drug treatment strategy for clinically treating NASH, and has significant clinical application value and market prospect.

The application discloses application of an Ilicium fortunei extract in preparation of a product for preventing and treating non-alcoholic fatty liver disease. The Ilicium fortunei extract is prepared through a water extraction-alcohol precipitation-dialysis impurity removal and macroporous resin decolorization process, has a sugar content of 36.23+1.56%, a sugar acid content of 46.00+1.77%, a protein content of 1.03+0.02% and a polyphenol content of 0.07+0.001%. Experimental results show that the extract can significantly reduce the body weight, liver weight and serum transaminase level of a mouse with metabolic disorder induced by a high-fat diet, improve glucose tolerance and insulin resistance, reduce liver steatosis and inflammatory damage, and effectively regulate intestinal flora structure and restore microbial community balance, thereby playing an intervention role on metabolic related fatty liver disease. The application provides a scientific basis for a new use of the Ilicium fortunei extract in prevention and treatment of metabolic related fatty liver disease, and has a good application prospect.

The application discloses application of protosappanin A in preparation of a medicine for treating liver fibrosis, relates to the technical field of biological medicine, and is used for reducing liver fibrosis by targeting CHEK1-mediated proliferation of hepatic stellate cells; the protosappanin A is used for reducing inflammation infiltration, necrosis and collagen deposition of the liver in the liver fibrosis; the medicine comprises protosappanin A and pharmaceutically acceptable adjuvants; the medicine is used for inhibiting activation and / or proliferation of hepatic stellate cells; the medicine is used for reducing liver fibrosis by down-regulating expression levels of CHEK1; a medicine composition for treating liver fibrosis comprises an effective amount of protosappanin A and pharmaceutically acceptable adjuvants; the application discloses a new use of protosappanin A (PrA) in preparation of an anti-liver fibrosis medicine; in-vivo and in-vitro experiments prove that PrA can significantly reduce serum transaminase (ALT, AST) levels, and reduce inflammation infiltration, necrosis and collagen deposition of the liver.

The invention provides an application of selenium-rich probiotics in preparation of a preparation for treating fluoxetine-induced liver injury, and relates to the technical field of biological medicine, the application is characterized in that Se-BL is obtained by reducing sodium selenite through ascorbic acid and modifying the surface of bifidobacterium longum, and nano-scale selenium dots are formed. The preparation plays a role through dual mechanisms: active oxygen (ROS) is directly removed, an Nrf2 pathway is activated, and the liver oxidation resistance (GSH, SOD) is improved; the traditional Chinese medicine composition is capable of inhibiting NF-kappa B inflammation signal channels, reducing proinflammatory factors (TNF-alpha and IL-6) and synchronously regulating intestinal flora so as to enhance the intestinal barrier function. Experiments prove that the traditional Chinese medicine composition can remarkably reduce the level of serum transaminase (ALT / AST / ALP) and relieve liver tissue necrosis and lipid peroxidation damage (MDA), the dosage form of the traditional Chinese medicine composition is an oral preparation, and each dose of the traditional Chinese medicine composition contains 1 * 10 <-1 > * 10 <-1 > CFU of Se-BL viable bacteria. The selenium-modified probiotics are used for antagonizing hepatotoxicity of mental drugs for the first time, and an innovative therapy is provided for fluoxetine-induced drug-induced liver injury (DILI) and acute hepatic failure (ALF).

The invention relates to the technical field of health food, and discloses a composition for sobering up, assisting in lowering lipid and improving intestinal tracts and a preparation method, the composition comprises the following components in parts by weight: 40-60 parts of rubus stems and leaves, 3-6 parts of oldenlandia diffusa, 1-3 parts of sculellaria barbata, 0.5-2 parts of balsam pear, 0.5-2 parts of radix bupleuri, 0.5-2 parts of pericarpium citri reticulatae, 0.5-2 parts of elecampane, 0.5-2 parts of raw hawthorn and 0.5-2 parts of semen plantaginis. The preparation method comprises the steps of raw material crushing, enzymolysis extraction, alcohol extraction, water extraction, spray drying and the like. Experimental verification shows that the composition has multiple effects of prolonging the drunkenness latency period, accelerating ethanol metabolism, reducing serum transaminase, regulating blood lipid indexes, improving intestinal peristalsis and flora structures and the like, and acute toxicity tests prove that the composition is high in edible safety. The composition disclosed by the invention can be used for preparing health-care foods with the effects of dispelling the effects of alcohol, assisting in lowering lipid and improving intestinal functions.

Use of apolipoprotein H (APOH) in the manufacture of medicaments for prevention and / or treatment of fatty liver disease and related diseases is provided. Using wild type C57BL / 6 mice as controls, the serum transaminase level in peripheral blood of 10-week-old ApoH gene knockout mice (C57BL / 6 ApoH− / −) was assessed. The results showed that the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are significantly increased. The triglyceride (TG) level was further assessed in the liver and the results showed that the TG level was significantly increased in the liver of ApoH− / − mice. Based on the findings that low APOH expression induces steatohepatitis, promotes the progression of chronic liver diseases (CLDs), and is related to the prognosis of end-stage liver diseases, it is conducive to the development of precise targeted therapeutic drugs for treating fatty liver disease and improving the prognosis of the end-stage liver diseases.

The invention discloses application of protocurcuma zedoary diol in preparation of a medicine for preventing and / or treating hepatic fibrosis, and belongs to the technical field of medicines. Specifically speaking, it is found that the protocurcuma zedoary diol can inhibit activation of hepatic stellate cells by up-regulating expression of brain expression X-linked protein 1 (BEX1) and effectively improve liver function indexes and liver pathological states, so that the purpose of treating hepatic fibrosis is achieved. Experimental results show that the protocurcuma zedoary diol can remarkably inhibit proliferation of hepatic stellate cells in vitro and can remarkably reduce the serum transaminase level and the hepatic fibrosis degree of hepatic fibrosis model rats in vivo. The invention also discloses a pharmaceutical composition containing the protocurcuma zedoary diol. The original curcuma zedoary diol provides a new candidate medicine for treating hepatic fibrosis.

The application discloses a kind of pharmaceutical compositions, it includes stilben compound and pharmaceutically acceptable adjuvant;Wherein, the stilben compound is Pterostilbene or its pharmaceutically acceptable salt, the pharmaceutically acceptable adjuvant includes glucosyl tangeritin and / or glycyrrhizic acid salt.The in vitro and / or in vivo test results show that the pharmaceutical composition provided by the application has good curative effect for preventing and / or treating drug-induced liver injury;Meanwhile, it can also significantly reduce serum transaminase level, alleviate the symptoms such as liver and spleen edema, and also has good inhibitory effect on proinflammatory cytokines.The test results further show that stilben compound and pharmaceutically acceptable adjuvant (including glucosyl tangeritin and / or glycyrrhizic acid salt) combination, good safety, and easy to dissolve, release and / or absorption etc., improve the bioavailability of Pterostilbene (PTE), have synergistic effect, and have good application prospect.

This invention discloses the application of ornithine aspartate in the preparation of drugs for treating systemic aging. By applying ornithine aspartate to regulate the systemic aging process, this invention can effectively improve hepatocyte dysfunction, restore cell proliferation activity, alleviate cell cycle arrest, and reduce the abnormal expression of aging-related genes and proteins in multiple tissues and organs such as the liver, kidneys, heart, muscles, and fat, thereby delaying the aging process. This technical solution can significantly improve the structural disorder and lipid deposition in aging liver tissue, reduce serum transaminase levels, improve liver function, reduce insulin resistance, inhibit the overexpression of SASP-related inflammatory factors, and maintain metabolic homeostasis. Furthermore, it effectively improves aging phenotypes in multiple tissues and organs. Therefore, this invention has significant technical effects and application potential in delaying systemic aging and improving motor function and metabolic abnormalities.

The invention relates to the technical field of functional food biology, and discloses a preparation method of highland barley vinasse polypeptide oral liquid for activating ethanol dehydrogenase, highland barley vinasse is used as a raw material, an ultrasonic-assisted alkaline protease enzymolysis technology is adopted, directional enzymolysis is carried out under an optimal process, and active polypeptide components with the molecular weight smaller than 3000Da are cut off through ultrafiltration, so that the highland barley vinasse polypeptide oral liquid is obtained. And then scientifically compounding with a honey extracting solution and a sea-buckthorn diluent. Through identification, the polypeptide component is rich in specific active peptide fragments such as LGAPF and the like. Animal experiments prove that the oral liquid can significantly improve the activity of ethanol dehydrogenase and acetaldehyde dehydrogenase in vivo and effectively reduce serum transaminase and liver lipid peroxidation level; the action mechanism relates to up-regulation of lipid metabolism gene expression and regulation of key intestinal flora abundance such as Muraculum and the like. According to the invention, high-valued utilization of the highland barley vinasse resource is realized, and the prepared product has remarkable comprehensive effects of dispelling the effects of alcohol, protecting liver and improving intestinal microecology.

The present invention pertains to the field of nutraceuticals, specifically to a synergistic nutraceutical composition designed to improve cardio-metabolic health. The composition, comprising berberine, anthocyanin(s), and astaxanthin, is intended to regulate aberrant metabolic biomarkers, including hyperglycemia, hypertriglyceridemia, elevated low-density lipoprotein (LDL) cholesterol, increased blood pressure, enhanced platelet aggregation, elevated serum transaminase activity and hypoadiponectinemia. This invention is particularly applicable to the therapeutic management of cardiometabolic pathologies, including Type 2 Diabetes Mellitus (T2DM), arterial hypertension, dyslipidemia, atherosclerosis, obesity, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), cerebrovascular accidents (stroke), and coronary artery disease, through the modulation of systemic metabolic homeostasis and by providing potential adjunctive efficacy alongside established pharmacotherapeutic regimens.

The application discloses application of ornithine aspartate in preparation of a medicine for treating systematic aging, and the ornithine aspartate is used to regulate the systematic aging process of a body, so that the liver cell dysfunction can be effectively improved, cell proliferation activity can be recovered, cell cycle arrest can be reduced, abnormal expression of aging-related genes and proteins in multiple tissues and organs such as liver, kidney, heart, muscle and fat can be reduced, and the aging process can be delayed. The technical scheme can significantly improve structural disorder and lipid deposition of the aging liver tissue, reduce the serum transaminase level, improve the liver function, reduce insulin resistance, inhibit excessive expression of SASP-related inflammatory factors, and maintain metabolic homeostasis. And the aging phenotype in multiple tissues and organs can be effectively improved. Therefore, the application has significant technical effects and application potential in delaying systematic aging, improving exercise function and metabolic abnormalities.